SG170796A1 - Methods for improving the pharmacokinetics of hiv integrase inhibitors - Google Patents

Methods for improving the pharmacokinetics of hiv integrase inhibitors

Info

Publication number
SG170796A1
SG170796A1 SG201102229-0A SG2011022290A SG170796A1 SG 170796 A1 SG170796 A1 SG 170796A1 SG 2011022290 A SG2011022290 A SG 2011022290A SG 170796 A1 SG170796 A1 SG 170796A1
Authority
SG
Singapore
Prior art keywords
hiv integrase
pharmacokinetics
improving
methods
integrase inhibitors
Prior art date
Application number
SG201102229-0A
Other languages
English (en)
Inventor
Brian P Kearney
Atsuyuki Kakee
Isao Kawaguchi
Original Assignee
Gilead Sciences Inc Us
Japan Tobacco Inc Jp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc Us, Japan Tobacco Inc Jp filed Critical Gilead Sciences Inc Us
Publication of SG170796A1 publication Critical patent/SG170796A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG201102229-0A 2005-12-30 2006-12-29 Methods for improving the pharmacokinetics of hiv integrase inhibitors SG170796A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75503905P 2005-12-30 2005-12-30
US75663106P 2006-01-06 2006-01-06
US76390106P 2006-02-01 2006-02-01

Publications (1)

Publication Number Publication Date
SG170796A1 true SG170796A1 (en) 2011-05-30

Family

ID=38016698

Family Applications (2)

Application Number Title Priority Date Filing Date
SG201102229-0A SG170796A1 (en) 2005-12-30 2006-12-29 Methods for improving the pharmacokinetics of hiv integrase inhibitors
SG201102227-4A SG170795A1 (en) 2005-12-30 2006-12-29 Methods for improving the pharmacokinetics of hiv integrase inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG201102227-4A SG170795A1 (en) 2005-12-30 2006-12-29 Methods for improving the pharmacokinetics of hiv integrase inhibitors

Country Status (16)

Country Link
US (1) US20070219243A1 (ru)
EP (2) EP2308490A1 (ru)
JP (1) JP4676536B2 (ru)
KR (3) KR20140082858A (ru)
CN (1) CN104069108A (ru)
AP (1) AP2702A (ru)
AU (1) AU2006332664B2 (ru)
BR (1) BRPI0620865A2 (ru)
CA (2) CA2847871C (ru)
EA (2) EA018544B1 (ru)
HR (1) HRP20080313A2 (ru)
IL (1) IL192208A (ru)
NO (1) NO20083333L (ru)
NZ (1) NZ569576A (ru)
SG (2) SG170796A1 (ru)
WO (1) WO2007079260A1 (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090233964A1 (en) * 2005-12-30 2009-09-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
LT2487166T (lt) 2007-02-23 2016-11-10 Gilead Sciences, Inc. Terapinių agentų farmakokinetinių savybių moduliatoriai
WO2009006203A1 (en) * 2007-06-29 2009-01-08 Gilead Sciences, Inc. Therapeutic compositions and the use thereof
JP5547066B2 (ja) * 2007-06-29 2014-07-09 ギリアード サイエンシーズ， インコーポレイテッド 治療用組成物およびその使用
WO2009092002A1 (en) * 2008-01-17 2009-07-23 Duquesne University Of The Holy Spirit Antiretroviral drug formulations for treatment of children exposed to hiv/aids
KR20170078868A (ko) 2010-01-27 2017-07-07 비이브 헬쓰케어 컴퍼니 항바이러스 치료
US8703786B2 (en) * 2011-12-07 2014-04-22 Texas Southern University Etravirine formulations and uses thereof
ES2926068T3 (es) 2012-12-21 2022-10-21 Gilead Sciences Inc Compuestos de carbamoilpiridona policíclicos y su uso farmacéutico
PT3252058T (pt) 2013-07-12 2021-03-09 Gilead Sciences Inc Compostos policíclicos-carbamoílpiridona e seu uso para o tratamento de infecções por hiv
NO2865735T3 (ru) 2013-07-12 2018-07-21
NO2717902T3 (ru) 2014-06-20 2018-06-23
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
TWI738321B (zh) 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
RS62434B1 (sr) 2014-12-26 2021-11-30 Univ Emory Antivirusni n4-hidroksicitidin derivati
ES2837383T3 (es) 2015-04-02 2021-06-30 Gilead Sciences Inc Compuestos de carbamoilpiridonas policíclicos y su utilización farmacéutica
SG11201802983TA (en) 2015-11-09 2018-05-30 Gilead Sciences Inc Therapeutic compositions for treatment of human immunodeficiency virus
CN111372592A (zh) 2017-12-07 2020-07-03 埃默里大学 N4-羟基胞苷及衍生物和与其相关的抗病毒用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552558A (en) 1989-05-23 1996-09-03 Abbott Laboratories Retroviral protease inhibiting compounds
US5354866A (en) 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
DK0727419T3 (da) 1992-12-29 2002-06-10 Abbott Lab Mellemprodukter til fremstilling af forbindelser, som inhiberer retroviral protease
US5567823A (en) 1995-06-06 1996-10-22 Abbott Laboratories Process for the preparation of an HIV protease inhibiting compound
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
TR200103488T2 (tr) * 1999-06-04 2002-04-22 Abbott Laboratories Geliştirilmiş farmasötik formülasyonlar.
US6541515B2 (en) * 2000-08-09 2003-04-01 Merck & Co., Inc. HIV integrase inhibitors
US6407128B1 (en) * 2001-12-03 2002-06-18 Elan Pharmaceuticals, Inc. Method for increasing the bioavailability of metaxalone
TWI286476B (en) * 2001-12-12 2007-09-11 Tibotec Pharm Ltd Combination of cytochrome P450 dependent protease inhibitors
AU2003301439A1 (en) 2002-10-16 2004-05-04 Gilead Sciences, Inc. Pre-organized tricyclic integrase inhibitor compounds
CA2470365C (en) * 2002-11-20 2011-05-17 Japan Tobacco Inc. 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
JP3567162B1 (ja) * 2002-11-20 2004-09-22 日本たばこ産業株式会社 ４−オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用
CA2513141A1 (en) * 2003-01-27 2004-08-12 Pfizer Inc. Hiv-integrase inhibitors, pharmaceutical compositions, and methods for their use
EP1622615A4 (en) * 2003-05-13 2009-02-18 Smithkline Beecham Corp INHIBITORS OF THE INTEGRASE OF NAPHTHYRIDINE
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
US7531554B2 (en) * 2004-05-20 2009-05-12 Japan Tobacco Inc. 4-oxoquinoline compound and use thereof as HIV integrase inhibitor
JP4629104B2 (ja) * 2004-05-21 2011-02-09 日本たばこ産業株式会社 ４−オキソキノリン誘導体および抗ｈｉｖ剤を含む併用剤
NZ563361A (en) * 2005-06-02 2011-02-25 Schering Corp HCV protease inhibitors in combination with food
US20090233964A1 (en) * 2005-12-30 2009-09-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
TWI411602B (zh) * 2006-09-12 2013-10-11 Gilead Sciences Inc 製造整合酶抑制劑的方法及彼所用的中間物
JP5547066B2 (ja) * 2007-06-29 2014-07-09 ギリアード サイエンシーズ， インコーポレイテッド 治療用組成物およびその使用
WO2009006203A1 (en) * 2007-06-29 2009-01-08 Gilead Sciences, Inc. Therapeutic compositions and the use thereof
AR068403A1 (es) * 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa

Also Published As

Publication number Publication date
WO2007079260A9 (en) 2007-08-30
EP2308490A1 (en) 2011-04-13
CN104069108A (zh) 2014-10-01
JP4676536B2 (ja) 2011-04-27
JP2009525265A (ja) 2009-07-09
IL192208A (en) 2013-10-31
SG170795A1 (en) 2011-05-30
EA200801619A1 (ru) 2008-10-30
KR20140082858A (ko) 2014-07-02
AU2006332664A1 (en) 2007-07-12
EA018544B1 (ru) 2013-08-30
AP2702A (en) 2013-07-23
EA201201496A1 (ru) 2013-07-30
CA2635468A1 (en) 2007-07-12
KR20160074018A (ko) 2016-06-27
NO20083333L (no) 2008-09-29
CA2847871C (en) 2016-07-26
CA2847871A1 (en) 2007-07-12
KR20080081358A (ko) 2008-09-09
HRP20080313A2 (en) 2008-11-30
IL192208A0 (en) 2009-02-11
WO2007079260A1 (en) 2007-07-12
NZ569576A (en) 2011-09-30
US20070219243A1 (en) 2007-09-20
KR101524165B1 (ko) 2015-06-01
AU2006332664B2 (en) 2013-03-14
BRPI0620865A2 (pt) 2011-11-29
CA2635468C (en) 2016-08-09
EP1976517A1 (en) 2008-10-08
AP2008004522A0 (en) 2008-06-30

Similar Documents

Publication Publication Date Title
SG170796A1 (en) Methods for improving the pharmacokinetics of hiv integrase inhibitors
ZA202208783B (en) Kras mutant protein inhibitors
MY197700A (en) Compounds useful for inhibiting cdk7
MX2012007375A (es) 3-ceto-n-propargil 1-aminoindano.
WO2017109488A8 (en) Cyanopyrrolidine derivatives as inhibitors for dubs
GEP20135791B (en) Use of dipeptidyl peptidase inhibitors
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
WO2005077050A3 (en) Hiv integrase inhibitors
WO2008033798A3 (en) A pyrrolopyrazin as syk-kinase inhibitor
AU2012236166A8 (en) Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods of use
MX2009006228A (es) Inhibidores de aspartil proteasa.
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
MY140514A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
WO2009144555A8 (en) Pyrazolospiroketone acetyl-coa carboxylase inhibitors
WO2013006451A3 (en) Macrocyclic insulin-degrading enzyme (ide) inhibitors and uses thereof
MXPA06000675A (es) Derivado de quinolona o sal del mismo.
GEP20115230B (en) Pyridinaminosulfonyl substituted benzamides as inhibitors of cytochrome p450 3a4
WO2005094810A3 (en) Novel pharmaceutical compositions
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
WO2006124684A3 (en) Combination therapy comprising a taxane and a thymidylate synthase inhibitor
WO2003065987A3 (en) Granzyme b inhibitors
EP2639229A3 (en) Thiazole Derivative and use thereof as VAP-1 Inhibitor
TW200738700A (en) HIV integrase inhibitors
WO2008011117A3 (en) Antiviral protease inhibitors
WO2001056573A8 (en) Use of cox-2 inhibitors as gastroprokinetics